736-P: Effect of Semaglutide on Liver Steatosis/Fibrosis Indexes in Patients with Diabetes and Obesity

736-P: Effect of Semaglutide on Liver Steatosis/Fibrosis Indexes in Patients with Diabetes and Obesity

Aim: To assess the efficacy of Semaglutide on liver steatosis/fibrosis indexes. Methods: Observational, multicenter study. Steatosis/fibrosis were determined by HSI (36 steatosis) and FIB-4 (2.67 fibrosis) . Results: 213 patients (46.9% women) , age 64 (19) years. Variables and 24 wk changes are sho...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diabetes (New York, N.Y.) N.Y.), 2022-06, Vol.71 (Supplement_1)
Hauptverfasser: GOMEZ, JUANA CARRETERO, CARRASCO-SÁNCHEZ, FRANCISCO JAVIER, FERNANDEZ, JOSE MARIA, CASADO, PEDRO, AREVALO LORIDO, JOSE CARLOS, GONZÁLEZ, JOSE PABLO MIRAMONTES, SEGÍ-RIPOLL, JOSÉ MIGUEL, ENA, JAVIER
Format: Artikel
Sprache:eng
Schlagworte:
Antidiabetics
Biomarkers
Body weight loss
Diabetes
Diabetes mellitus
Fatty liver
Fibrosis
Obesity
Steatosis
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Aim: To assess the efficacy of Semaglutide on liver steatosis/fibrosis indexes. Methods: Observational, multicenter study. Steatosis/fibrosis were determined by HSI (36 steatosis) and FIB-4 (2.67 fibrosis) . Results: 213 patients (46.9% women) , age 64 (19) years. Variables and 24 wk changes are shown in table 1. 100% of patients had altered steatosis biomarkers (HSI 47.9 (8.2)) , 10.8% fibrosis (FIB-4> 2.76) . A significant reduction in HSI [-2.36 (95%CI 1.83-2.9) p
ISSN:0012-1797
1939-327X
DOI:10.2337/db22-736-P